Why Did INmune Bio Plunge 13.19%?

On August 1, 2025, INmune Bio's stock price plummeted by 13.19% in pre-market trading, marking a significant decline for the biotechnology company.

INmune Bio, a biotechnology company focused on developing therapies for autoimmune diseases and cancer, has been facing challenges in recent months. The company's stock has been under pressure due to a lack of positive news and updates on its clinical trials. Investors have been growing impatient with the slow progress, leading to a sell-off in the stock.

Additionally, the company's recent financial performance has raised concerns among investors. INmune Bio reported a net loss for the second quarter of 2025, which was wider than expected. The company's cash position has also been a source of concern, as it has limited financial resources to fund its operations and clinical trials.

Despite these challenges, INmune Bio remains focused on advancing its pipeline of therapies. The company is currently conducting clinical trials for several of its drug candidates, including XPro1595, a therapy for Alzheimer's disease, and INB03, a therapy for multiple sclerosis. The success of these trials will be crucial for the company's future prospects.